Skip to main content
Article
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis
Rheumatology (2018)
  • Mark C Genovese, Stanford University
  • Michael E Weinblatt, Brigham and Women's Hospital
  • Philip J Mease, University of Washington
  • Jacob A Aelion, University of Tennessee Health Science Center
  • Paul M Peloso, Clinical Development, AbbVie Inc., North Chicago, IL, USA
  • Kun Chen, Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA
  • Yihan Li, Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA
  • John Liu, National Patient Safety Foundation
  • Ahmed A Othman, Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA
  • Amit Khatri, Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA
  • Heikki T Mansikka, Clinical Development, AbbVie Inc., North Chicago, IL, USA
  • Piotr Leszczyński, Poznan University of Medical Sciences
Publication Date
November 1, 2018
DOI
10.1093/rheumatology/key173
Citation Information
Mark C Genovese, Michael E Weinblatt, Philip J Mease, Jacob A Aelion, et al.. "Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis" Rheumatology Vol. 57 Iss. 11 (2018) p. 1972 - 1981
Available at: http://works.bepress.com/philip-mease/354/